Analysis Presented at World GI Cancer Conference Highlights Variability in Global Practice Patterns in Treating Metastatic Colorectal Cancer

Share Article

Clinical Care Options’ data presented at ESMO GI 2018 show heterogeneous practice patterns within several CRC subtypes and settings

The online tool provides up-to-date expert recommendations based on the most recent clinical data to help educate clinicians on the optimal care of their patients. - Tanios Bekaii-Saab, MD

Healthcare providers showed discordance from that of 5 US-based expert recommendations in their treatment selection for patients with metastatic colorectal cancer (mCRC) in the settings of first-line therapy for right-sided RAS/BRAF wild type and BRAF V600E mutation, second-line therapy for left-sided RAS/BRAF wild type, and third-line therapy for RAS-mutant and high microsatellite instability tumors, according to an analysis of data captured from an online treatment decision support tool developed by Clinical Care Options (CCO) in collaboration with a panel of mCRC experts. The results were presented at the 20th Annual World GI Cancer Conference in Barcelona, Spain.

The analysis was conducted by CCO’s Krista Marcello in conjunction with Tanios Bekaii-Saab, MD; George A. Fisher, MD, PhD; Scott Kopetz, MD, PhD; John H. Strickler, MD; and Alan P. Venook, MD.

“This significant heterogeneity in opinion speaks to the fact that we have many more choices for treating patients with mCRC across multiple lines of therapy as we are learning to individualize our treatment based on molecular characteristics and prior therapy exposure,” said Tanios Bekaii-Saab, MD, Program Co-Leader of the GI Cancer for the Mayo Clinic Cancer Center, Phoenix, Arizona. “These are excellent advancements for patients and their healthcare providers; however, it can also challenge clinicians to offer the best care for their patients with mCRC. The online tool provides up-to-date expert recommendations based on the most recent clinical data to help educate clinicians on the optimal care of their patients.”

“CCO is proud to be part of this ongoing collaboration and pleased to share the findings of this study with the global medical community at large,” said Tina Stacy, PharmD, BCOP, CHCP, Executive Vice President, Educational Strategy and General Manager, Oncology at CCO. “As part of our ongoing commitment to improving patient care, we strive to create innovative technology to assess and directly address any identified clinical practice challenges.”

The goal now is to continue to update this online tool as the treatment of patients with mCRC evolves to provide a useful resource for healthcare providers and patients. The most recent version of this tool can be found at http://www.clinicaloptions.com/CRCtool.

About Clinical Care Options
Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO’s team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com.

Contact:
Tradd Sanderson | Director of Marketing
Clinical Care Options
Telephone: 855.224.2241
Email: tsanderson(at)clinicaloptions.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carlton Sanderson

Tradd Sanderson
Visit website